Verve’s single CRISPR infusion held monkey triglycerides 43% lower for three years

Researchers at Verve Therapeutics, an Eli Lilly subsidiary, and collaborating institutions report in Nature that one infusion of a CRISPR base editor was associated with lower blood fats in monkeys for three years. The treatment packages RNA for a base editor and a guide inside GalNAc-decorated lipid nanoparticles. The guide directs a one-letter DNA change in ANGPTL3, a liver gene whose protein slows clearance of fats from the blood. Ten animals with normal lipids received the active formulation. Verve funded the work; most authors are employees, and several hold Lilly shares or are named on related patents.

In that durability experiment, mean ANGPTL3 protein was about 94% below pretreatment levels. Triglycerides averaged 43% lower and LDL cholesterol 13% lower. Liver samples showed similar editing at seven weeks and at three years. In a shorter test, four monkeys with a disrupted LDL-receptor gene, a model of homozygous familial hypercholesterolemia, had mean LDL fall from 458 to 247 milligrams per deciliter by day 35, a 46% drop. That arm did not establish years of lowering. Liver enzymes rose, then returned to baseline within two weeks, with no lasting toxicity reported.

ANGPTL3 is already a drug target. Evinacumab, an antibody used in a severe inherited cholesterol disorder, blocks the protein but is given about every four weeks. Editing is meant to stop the liver from making it after one course. Ordinary lipid nanoparticles rely heavily on LDL receptors to enter liver cells; GalNAc uses another receptor, which is why receptor-deficient animals were tested. In cultured human liver cells, the human candidate VERVE-201 showed no detectable unintended edits at roughly 3,000 candidate sites. That search cannot exclude every unwanted DNA change. These are primate experiments, not a human outcomes trial.

People with high LDL or triglycerides, and especially those with homozygous familial hypercholesterolemia, now rely on repeated treatment: daily lipid-lowering drugs or, for ANGPTL3 blockade, antibody infusions about every four weeks. This study associates one edit with large, sustained drops in ANGPTL3 and triglycerides, and a smaller LDL change in animals that started with normal lipids. It cannot show fewer heart attacks, human durability, or that editing should replace statins. Company funding, employee authorship, Lilly shares, and related patents are conflicts that limit how much weight one sponsored animal report should carry on its own. VERVE-201 is in a phase 1b trial for inadequately controlled blood lipids.